Gilead is partnering with insitro to develop therapies for fatty liver disease non-alcoholic steatohepatitis (NASH), as the recently flunked a key phase 3 NASH trial. The privately held insitro uses machine learning techniques to create large, high-quality data sets to help address problems in the drug discovery and development process.
Gilead is paying insitro $15 million upfront with additional near-term payments up to $35 million based on operational milestones. Gilead also signed a deal with Novo Nordisk for another potential NASH treatment, combining Novo Nordisk’s semaglutide and its own cilofexor and firsocostat.
Read the Reuters report.